Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48week results from two Phase 3 studies (Studies 104 and 111)…